2020
Endometriosis Pain Management: a Review
Carlyle D, Khader T, Lam D, Vadivelu N, Shiwlochan D, Yonghee C. Endometriosis Pain Management: a Review. Current Pain And Headache Reports 2020, 24: 49. PMID: 32671581, DOI: 10.1007/s11916-020-00884-6.Peer-Reviewed Original ResearchConceptsSurgical managementGnRH agonists/antagonistsNonsteroidal anti-inflammatory drugsPain management optionsAnti-inflammatory drugsAgonists/antagonistsNerve ablationPresacral neurectomyMedical managementTreatment modalitiesAromatase inhibitorsChallenging diseaseSurgical techniqueReviewThe purposeNeurectomyExperimental pharmaceuticalsManagement optionsAblationHysterectomyOophorectomyEndometriosisRegimensResectionDanazolPatients
2015
Effects of ospemifene on the female reproductive and urinary tracts
Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD. Effects of ospemifene on the female reproductive and urinary tracts. Menopause The Journal Of The North American Menopause Society 2015, 22: 786-796. PMID: 25423325, PMCID: PMC4481022, DOI: 10.1097/gme.0000000000000365.Peer-Reviewed Original ResearchConceptsEstrogen receptor agonist/antagonistReceptor agonists/antagonistsAgonists/antagonistsVaginal atrophyVaginal tissueSelective estrogen receptor modulatorsEffects of ospemifenePostmenopausal women's healthRelief of symptomsEstrogen receptor modulatorsAgonist/antagonist effectsUrinary tract tissuesHormone-responsive tissuesTissue-dependent responseEndometrial histopathologyEndometrial safetyEstrogen therapyClinical effectsTransvaginal ultrasoundMenopausal symptomsUrinary tractPreclinical dataCytologic examinationVaginal effectsPreclinical models
2014
Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5)*
Haas LT, Kostylev MA, Strittmatter SM. Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5)*. Journal Of Biological Chemistry 2014, 289: 28460-28477. PMID: 25148681, PMCID: PMC4192497, DOI: 10.1074/jbc.m114.584342.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloid beta-PeptidesAnimalsAntibodiesBinding SitesBiological AssayBrain ChemistryCell MembraneDisease Models, AnimalGene Expression RegulationHEK293 CellsHumansLigandsMiceMice, TransgenicPeptide MappingProtein BindingProtein Structure, TertiaryPrPC ProteinsReceptor, Metabotropic Glutamate 5Recombinant ProteinsSignal TransductionSmall Molecule LibrariesConceptsMetabotropic glutamate receptor 5Glutamate receptor 5Receptor 5Endogenous ligandMouse brainAD transgenic model miceCellular prion proteinAmino acids 91Transgenic model miceSoluble amyloid β (Aβ) oligomersAlzheimer's disease pathophysiologySilent allosteric modulatorsAgonists/antagonistsExtracellular AβOsMGluR5 activitySynthetic AβOsPrion proteinAmyloid-β OligomersModel miceCell membrane preparationsMGluR5Neurotoxic signalsBrain homogenatesAlzheimer's diseaseDisease pathophysiology
2006
Androgen Effects on Hippocampal CA1 Spine Synapse Numbers Are Retained in Tfm Male Rats with Defective Androgen Receptors
MacLusky NJ, Hajszan T, Johansen JA, Jordan CL, Leranth C. Androgen Effects on Hippocampal CA1 Spine Synapse Numbers Are Retained in Tfm Male Rats with Defective Androgen Receptors. Endocrinology 2006, 147: 2392-2398. PMID: 16439462, DOI: 10.1210/en.2005-0673.Peer-Reviewed Original ResearchConceptsDefective androgen receptorHippocampal synaptic responsesEstradiol benzoateAndrogen receptorMale ratsSpine synapsesTfm malesSynaptic responsesAndrogen effectsTfm mutationEffects of EBDose of EBHippocampal CA1 synapsesSpine synapse numberSesame oil vehicleDendritic spine synapsesCA1 stratum radiatumAdult male ratsHippocampal spine synapsesVehicle-injected controlsHormone-induced increaseAgonists/antagonistsWild-type animalsWild-type malesCA1 synapses
2002
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.Peer-Reviewed Original ResearchConceptsAndrogen-independent human prostate cancer cell linesMixed estrogen agonist/antagonistProstate cancer cell linesHuman prostate cancer cell linesEstrogen agonist/antagonistAgonists/antagonistsCancer cell linesER betaER alphaCell linesDU145 cellsSelective estrogen receptor modulatorsEffects of raloxifeneEstrogen receptor modulatorsPC3M cellsDose-dependent mannerCell deathM raloxifeneWestern blot analysisTime-dependent mannerRaloxifene treatmentReceptor modulatorsBreast cancerPan-caspase inhibitor zVADRaloxifeneRaloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 2002, 62: 3649-53. PMID: 12097269.Peer-Reviewed Original ResearchConceptsSelective estrogen receptor modulatorsHuman prostate cancer cell line LNCaPAndrogen-independent pathwayProstate cancer cell line LNCaPCancer cell line LNCaPEstrogen receptor modulatorsCell line LNCaPLNCaP cellsER betaReceptor modulatorsAndrogen-sensitive human prostate cancer cell line LNCaPAndrogen-sensitive human prostate cancer cell line LNCaP.Mixed estrogen agonist/antagonistHuman prostate cancer cell line LNCaP.Estrogen agonist/antagonistProstate-specific antigen assaysEffects of raloxifeneProstate cancer cell line LNCaP.Androgen receptor activityPresence of antiandrogensDose-dependent mannerAgonists/antagonistsSelective ER modulatorsAndrogen response elementAntigen assaysRaloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*
Kim H, Kim B, Kim I, Mamura M, Seong H, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid Chloromethyl KetonesAntineoplastic AgentsApoptosisbcl-Associated Death Proteinbcl-X ProteinCarrier ProteinsCaspase 3CaspasesCell DivisionCell MembraneCell NucleusCycloheximideCytochrome c GroupDNA FragmentationDose-Response Relationship, DrugEstrogen Receptor ModulatorsHumansIn Situ Nick-End LabelingMembrane PotentialsMitochondriaPhosphorylationProtein BindingProtein Synthesis InhibitorsProto-Oncogene Proteins c-bcl-2Raloxifene HydrochlorideRetroviridaeTime FactorsTumor Cells, CulturedUrinary Bladder NeoplasmsConceptsMixed estrogen agonist/antagonistTSU-Pr1 cell linesEstrogen agonist/antagonistTSU-Pr1 cellsAgonists/antagonistsCell linesSelective estrogen receptor modulatorsHuman bladder transitional cell carcinoma cell lineEffects of raloxifeneTransitional cell carcinoma cell linesProstate cancer cell linesEstrogen receptor modulatorsCell carcinoma cell linesEstrogen receptor betaHuman bladder cancerDose-dependent mannerEvidence of apoptosisCancer cell linesRaloxifene treatmentCarcinoma cell linesBladder cancerReceptor modulatorsBreast cancerHuman cancer cellsRaloxifeneButorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure
Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacology Biochemistry And Behavior 2002, 71: 85-96. PMID: 11812511, DOI: 10.1016/s0091-3057(01)00637-2.Peer-Reviewed Original ResearchConceptsNaloxone-appropriate respondingOpioid antagonist naloxoneDose-related increaseAntagonist naloxoneNovel-response drug discrimination procedureOpioid agonist/antagonistOpioid-dependent humansDoses of naloxoneDiscriminative stimulus effectsDrug discrimination procedureAgonists/antagonistsAppropriate respondingLow doseHigh doseNaloxoneSelf-reported effectsDiscrimination procedureDrug conditionsHigh dosesNalbuphineButorphanolDosesDoseRespondingPlacebo
1992
Buprenorphine for cocaine and opiate dependence.
Kosten T, Rosen M, Schottenfeld R, Ziedonis D. Buprenorphine for cocaine and opiate dependence. Psychopharmacology Bulletin 1992, 28: 15-9. PMID: 1609037.Peer-Reviewed Original ResearchConceptsCocaine abuseMixed opioid agonist/antagonistOpioid agonist/antagonistPreliminary human studiesAgonists/antagonistsBuprenorphine treatmentOpioid dependenceMethadone maintenanceClinical trialsConcurrent dependencePreclinical studiesCocaine effectsBuprenorphineHuman studiesPlace preferenceChallenge studiesCocaineMethadoneTreatmentTrialsAbuseDose dependenceOpioidsAntagonistDailyBuprenorphine for Opioid and Cocaine Dependence
Rosen M, Kosten T. Buprenorphine for Opioid and Cocaine Dependence. Drug And Alcohol Abuse Reviews 1992, 137-147. DOI: 10.1007/978-1-4612-0359-9_7.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply